Clinical Trial Update: Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of pazopanib hydrochloride after leuprolide or goserelin in relapsed prostate cancer has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pazopanib hydrochloride (pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-10